NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics announced today that, pursuant to an agreement dated February 23, 2009, it has completed the private allocation of the company’s common stock to Meitav, a leading institutional investor in Israel. The placement resulted in gross proceeds to Kamada of approximately US$1.5 million.
